

CDH17 CAR T PRECLINICAL DATA FEATURED AS COVER STORY FOR PRESTIGIOUS JOURNAL NATURE CANCER

- A CAR T targeting the cell surface marker CDH17 (“CDH17 CAR”), currently under development by Chimeric as CHM 2101, is featured in the prestigious journal *Nature Cancer*, highlighting its strong scientific merit and innovation
- Preclinical data demonstrates strong evidence of efficacy with complete eradication of CDH17-expressing tumours with no toxicity

Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that the discovery and preclinical characterization of a CAR T targeting CDH17, currently under development by Chimeric as CHM 2101 has been published as the cover story for the highly prestigious journal ***Nature Cancer***.

Key findings highlighted in the *Nature Cancer* publication included:

- Strong preclinical safety and efficacy: the CDH17 CAR T completely eradicated tumours, with no relapse or toxicity, in 8 different *in vivo* models including colorectal cancer (CRC), gastric cancer, pancreatic cancer, and neuroendocrine tumours (NETs).
- Optimal CAR T construct design: the CDH17 CAR T as a third-generation CAR T cell construct was shown to be superior to the 2nd-generation CAR T cell construct, demonstrating complete elimination of solid tumours *in vivo*. Construct optimization with a very short linker domain further enhanced tumour cell killing.
- Tumour-specific activity: CDH17 CAR T cells infiltrated and destroyed CDH17⁺ tumours, but not normal CDH17-expressing tissues such as small and large intestines, creating a therapeutic window for CAR T treatment of solid tumours.

The authors conclude that their “findings indicate that CDH17 is an ideal target of CART therapy for GICs (Gastrointestinal Cancers) and NETs (Neuroendocrine Tumours)” and that their studies “suggest that CDH17 is a safe and efficacious target for developing CART therapy to treat GICs and NETs, without toxicity to healthy tissues, motivating further clinical investigation.”¹

The Nature Portfolio publishes a range of academic journals, magazines and online databases covering science and medicine, and is known to publish some of the world’s most highly prestigious scientific journals. The *Nature Cancer* journal ‘aims to publish the most significant advances across the full spectrum of cancer research in the life, physical, applied and social sciences, spanning basic preclinical, translational and clinical work’.



In July 2021, Chimeric acquired the exclusive rights to develop and commercialize CDH17 (CHM 2101), and in February 2022 announced its commitment to a three-year sponsored research program with the inventors to further the development and understanding of CHM 2101.

“The data published in Nature Cancer are rigorous, scientifically elegant, and suggest great promise for CHM 2101 as a potential CAR T-cell therapy for solid tumours,” said Eliot Bourk, Ph.D., Chimeric’s Chief Business Officer and Head of External Innovation. “The optimized construct targeting CDH17 presents a novel and highly differentiated approach to overcoming the challenges observed to date with T-cell therapies in solid tumours.”

“We are now rapidly advancing CHM 2101 toward first-in-human clinical studies, with the hope of bringing the promise of cell therapy to life for patients with currently incurable GI cancers,” said Chimeric CEO and Managing Director, Jennifer Chow.

1. Feng et al. Nature Cancer, 2022. <https://doi.org/10.1038/s43018-022-00344-7>

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer not just delay disease progression.

To bring that promise to life for more patients, Chimeric’s world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed by scientists at the City of Hope Medical Centre in California for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1 clinical trial in recurrent/ progressive glioblastoma. A 2nd CLTX CAR T phase 1 clinical trial is planned to begin in 2022 in additional solid tumours.

CHM 2101 (CDH17 CAR T) is a novel, 3rd generation CDH17 CAR T invented at the University of Pennsylvania. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in 2022 in Neuroendocrine Tumours, Colorectal, Pancreatic and Gastric Cancer.

Recently Chimeric announced the addition of the CORE-NK platform, a clinically validated, off the shelf natural killer (NK) cell therapy platform to their portfolio (CHM 0201). From the CORE-NK platform, Chimeric will initiate development of four new next generation NK and CAR NK assets with plans for phase 1 clinical trials to begin in 2023 in solid tumours and blood cancers.



Chimeric Therapeutics continues to be actively engaged in further developing its oncology pipeline with new and novel cell therapy assets that will bring the promise of cell therapy to life for more patients with cancer.

CONTACT

Investors

Jennifer Chow
Chief Executive Officer and Managing Director
Chimeric Therapeutics
T: + 1 9087238387
E: jchow@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Paul Hopper
Executive Chairman
Chimeric Therapeutics
T: + 61 406 671 515
E: paulhopper@lifescienceportfolio.com

Media

Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au